Please remember there have been a multitude of positive studies since the share price was $10.
It wont get Penthrox into UK ambulances or used in emergency rooms, not alone. Its been over 6 years since approval to sell Penthrox in the UK and the sales have been poor - nowhere near the per capita penetration we have in Australia.
We as shareholders need to keep the Board focussed on the sales strategy and in turn the Board keeps mgmt focussed on implementing that strategy. the current UK strategy is failing us as shareholders. Lets hope its different in France and elsewhere or we will soon have a shareprice much lower than where it is right now.
Another Positive Study, page-57
-
- There are more pages in this discussion • 112 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MVP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.0¢ |
Change
0.005(1.15%) |
Mkt cap ! $49.56M | |||
| Open | High | Low | Value | Volume |
| 43.5¢ | 45.0¢ | 43.0¢ | $72.64K | 164.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3355 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 15645 | 1 |
View Market Depth
| Last trade - 15.56pm 13/09/2024 (20 minute delay) ? |
| MVP (ASX) Chart |